Compare BTCT & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTCT | KPRX |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | Singapore | United States |
| Employees | 26 | 13 |
| Industry | Other Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 11.7M |
| IPO Year | N/A | N/A |
| Metric | BTCT | KPRX |
|---|---|---|
| Price | $0.52 | $2.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 319.0K | 20.1K |
| Earning Date | 05-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $283.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $1.76 |
| 52 Week High | $3.12 | $2.99 |
| Indicator | BTCT | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 25.18 | 53.94 |
| Support Level | N/A | $2.44 |
| Resistance Level | $1.21 | $2.61 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 1.12 | 88.57 |
BTC Digital Ltd is the ledger technology that underlies bitcoin and other cryptocurrencies, based in the U.S., with a focus on bitcoin mining. A blockchain is a decentralized, distributed, and encrypted digital public ledger that stores information in a secure, verifiable, and permanent way. The company also generates revenue through the resale of mining machines, mining machine rental, and miner hosting services.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.